Molecule Information

General Information of the Molecule (ID: Mol04254)

• Name: Forkhead box protein O1/Rapamycin-insensitive companion of mTOR (FOXO1/RICTOR) axis ,Homo sapiens
• Synonyms: Forkhead box protein O1/Rapamycin-insensitive companion of mTOR (FOXO1/RICTOR) axis
• Molecule Type: Protein

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Ibrutinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Disease Class: Chronic lymphocytic leukemia [ICD-11: 2A82.0] [1]

• Resistant Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Resistant Drug: Ibrutinib
• Molecule Alteration: Expression; p.Y537N
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: CD5+19+ cells; Blood; Homo sapiens (Human); N.A.
• In Vitro Model: MEC1 cells; Blood; Homo sapiens (Human); CVCL_1870
• In Vitro Model: HS-5 cells; Bone marrow; Homo sapiens (Human); CVCL_3720
• In Vivo Model: NSG mice model; Mus musculus
• Experiment for Molecule Alteration: Immunoblotting assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: Induction of transcription factor FoxO1 during ibrutinib therapy upregulates Rictor, an mTORC2 assembly protein, leading to phosphorylation of Akt, an essential molecule supporting CLL cell survival

References

• Ref 1: FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Invest. 2024 Oct 22;134(23):e173770.